Oligopeptide-1Growth-factor ingredient context
Oligopeptide-1 is often discussed in connection with epidermal growth factor, or EGF, in skincare. The exact ingredient identity and naming on a product need checking before clinical evidence can be matched to it.
What is Oligopeptide-1?
Oligopeptide-1 is often discussed alongside epidermal growth factor, or EGF, in skincare. Exact ingredient identity matters: recombinant names and supplier preparations should be checked before matching a product to a study.
How it works
EGF signals through its receptor to influence cell behaviour. A laboratory growth signal does not demonstrate effective passage through intact skin or show that increasing that signal improves a cosmetic outcome.
Effects studied
Skin appearance and post-procedure recovery
The retained references include cosmetic and clinical settings. Results in recently treated or damaged skin should not be treated as results in ordinary intact skin, and multi-ingredient formulas do not isolate EGF's contribution. 1 2
Evidence: Formulation- and setting-specific clinical leads.
What does the evidence show?
The archive includes clinical and cosmetic research leads. Their formulations and treatment settings need to match the product claim; the label alone does not establish that match.
Why the name needs care
EGF is a protein that signals to cells through the epidermal growth factor receptor. Cosmetic names can be confusing, especially for recombinant ingredients or supplier blends. To match a product to the evidence, the actual molecule and preparation must first be identified. An oligopeptide label alone does not establish that two products contain the same active ingredient.
What growth signalling can and cannot tell us
Stimulating a cell pathway in a laboratory provides a biological explanation worth investigating. It does not demonstrate that a cosmetic ingredient crosses intact skin in an effective form or that more signalling is necessarily beneficial. Delivery and the condition of the skin both change the question.
Post-procedure skin is a special setting
Studies after procedures or in damaged skin should not be silently treated as trials in ordinary intact skin. The barrier, accompanying care and clinical supervision differ. Likewise, a multi-ingredient cosmetic result cannot isolate EGF’s contribution without an appropriate comparison. 1 2
A useful description avoids sweeping promises
A serum’s claimed benefit needs to match the appearance change measured with the tested preparation. “Cell regeneration” is too broad to describe either benefit or risk. Use on broken or recently treated skin requires guidance for that particular product; ordinary skincare use does not establish suitability in those settings.
Safety & status
Broken or recently treated skin needs product-specific guidance. Normal skincare use does not establish suitability immediately after a procedure.
Country and product status
This page describes a cosmetic ingredient and its research context. Permitted claims and product availability in Germany and Switzerland need a local check. An ingredient listing does not establish approval to treat a medical condition.
Frequently asked questions
Does the ingredient name guarantee that a serum contains the EGF used in a trial?
No. The actual molecule, preparation and formulation must be matched to the evidence.
Does growth-factor activity prove skin regeneration?
No. That phrase combines many possible outcomes; a useful claim names the measured change in people.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Oligopeptide-1: paper 10.1111/jocd.70927 Research reference · Retained archive reference; not independently checked for this draft.
- Oligopeptide-1: paper 10.1111/jocd.12977 Research reference · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.